PolyNovo (ASX:PNV): Synthetic Skin Repair Technology Supports Medical Device Expansion

Sonal Goyal

18 September 2026 06:35 PM AEST

PolyNovo (ASX:PNV): Synthetic Skin Repair Technology Supports Medical Device Expansion

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

PolyNovo (ASX:PNV) develops synthetic biodegradable polymer technology for skin and soft tissue repair.
NovoSorb remains the company’s core technology platform across wound care applications.
The company continues expanding its presence in the United States and other international markets.
Product adoption, commercial expansion and Manufacturing execution remain key areas to monitor.

PolyNovo Limited (ASX:PNV) is an Australian medical device company focused on developing synthetic solutions for complex wound and tissue repair. Its NovoSorb technology platform is designed to support skin regeneration following severe burns, trauma and other challenging wounds. This article examines how the company’s synthetic approach and product portfolio support its healthcare strategy.

The NovoSorb Technology Platform

NovoSorb is a biodegradable synthetic polymer platform used to create dermal scaffolds for wound repair. The technology provides a manufactured alternative to biological graft materials, allowing the company to control production, consistency and supply.

The company’s core product, NovoSorb BTM, is used as a temporary matrix that supports tissue regeneration before skin grafting procedures. The platform is also being expanded through additional products targeting different wound care applications.

Product Portfolio Expansion

NovoSorb BTM remains the company’s main commercial product, while NovoSorb MTX has expanded the platform into broader dermal repair applications. PolyNovo has also been developing SynPath, a product aimed at chronic wound settings.

The common foundation across these products is the NovoSorb polymer technology, which provides a consistent manufacturing approach across multiple medical applications.

United States Market Development

The United States remains an important market for PolyNovo. The company has continued building its commercial presence through hospital engagement and expansion of its sales capabilities.

Growing adoption in international markets requires continued engagement with healthcare providers, regulatory compliance and support for clinical workflows.

Business Considerations

PolyNovo’s growth depends on continued product adoption, maintaining manufacturing quality and expanding applications for its synthetic technology. Medical device markets require ongoing clinical support and healthcare provider confidence.

The company must also manage operational expansion while maintaining Supply capability across multiple geographic regions.

Key Insights

PolyNovo has developed a specialised synthetic wound care platform through NovoSorb technology. The company’s future progress will depend on expanding adoption of its products, broadening applications and continuing commercial execution across global healthcare markets.

FAQs

Q: What does PolyNovo develop?

A:PolyNovo develops synthetic biodegradable polymer products for wound and tissue repair.

Q: What is NovoSorb?

A:NovoSorb is PolyNovo’s synthetic polymer technology platform used in dermal repair products.

Q: What is NovoSorb BTM used for?

A:NovoSorb BTM is used as a dermal scaffold to support tissue regeneration.

Q: What factors may influence PolyNovo’s progress?

A:Product adoption, market expansion and manufacturing execution are key factors.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.